Sera Prognostics (SERA) Corporate presentation summary

Market need and healthcare impact

• Preterm birth rates in the US have risen from 9.4% to 10.4% between 2013 and 2024, with NICU admissions increasing from 8.7% to 9.8% between 2016 and 2023.

• Preterm births account for 61% of neonatal costs, with extremely premature births costing up to $344,355 per delivery and 7-year healthcare costs up to 7x higher than full-term births.

• Traditional screening methods fail to identify 81% of women who will experience preterm birth, and only 20% of mothers receive information on preterm labor risk at their first prenatal appointment.

Product and scientific innovation

• The PreTRM test is a proteomics-based, blood biomarker test that predicts spontaneous preterm birth risk early in pregnancy, using proteins such as IGFBP4 and SHBG.

• The test integrates seamlessly into prenatal care, with results delivered in five days and a negative predictive value of 97%.

• Supported by a biobank of 20,000 samples and 11+ published studies, the platform leverages AI and mass spectrometry for early risk prediction.

Clinical validation and outcomes

• PreTRM is the only clinically validated test for early prediction of preterm birth, verified by eight independent studies and a large multi-center trial.

• The PRIME randomized controlled trial (n=5,018) showed 20% fewer NICU admissions, 56% fewer births before 32 weeks, and a 20% reduction in neonatal morbidity odds.

• Targeted interventions for higher-risk pregnancies include low-dose aspirin, vaginal progesterone, and care management, leading to prolonged gestational age and reduced complications.